Pancreatic Cancer Research

ResearcherUniversity Hospital UlmActive in the last 2 years

Javier Gallego-Plazas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0584-1242; OpenAlex author ID A5017427348. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 0)
Trials
1
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2013: 1 trial · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 15

  1. Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort. Co-author DOI 10.1007/s12094-026-04554-8↗
  2. Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Co-author DOI 10.1016/j.pan.2026.08.008↗
  3. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  4. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1056/evidoa2300144↗
  5. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial. Co-author DOI 10.4251/wjgo.v16.i2.386↗
  6. Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993↗
  7. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Co-author DOI 10.1016/j.pan.2018.10.004↗
  8. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. Co-author DOI 10.1186/s12885-018-5101-3↗
  9. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Co-author DOI 10.1371/journal.pone.0194844↗
  10. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
  11. Biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-017-1691-5↗
  12. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … First author DOI 10.1016/j.ejca.2016.12.032↗
  13. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  14. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  15. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Co-author DOI 10.1007/s12094-014-1177-7↗

Trials 1

  1. Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of … Study director NCT01971281↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carmen Guillén‐Ponce · 9 shared papers, 2016–2026 · strength 1.02
  2. Alberto Carmona‐Bayonas · 5 shared papers, 2017–2026 · strength 0.76
  3. Vilma Pacheco-Barcía · 3 shared papers, 2024–2026 · strength 0.66
  4. Roberto Pazo-Cid · 6 shared papers, 2017–2024 · strength 0.53
  5. Andrés Jesús Muñoz Martín · 3 shared papers, 2018–2026 · strength 0.49
  6. Ángela Lamarca · 2 shared papers, 2026 · strength 0.45
  7. Elena Brozos-Vázquez · 2 shared papers, 2026 · strength 0.45
  8. Luis Cabezón‐Gutiérrez · 2 shared papers, 2024–2026 · strength 0.43
  9. Enrique Aranda · 5 shared papers, 2014–2024 · strength 0.39
  10. Fernando Rivera · 4 shared papers, 2014–2024 · strength 0.37
  11. Ismael Ghanem · 2 shared papers, 2022–2026 · strength 0.35
  12. Alfredo Carrato · 4 shared papers, 2014–2024 · strength 0.34
  13. Manuel Benavides · 5 shared papers, 2014–2019 · strength 0.33
  14. Ruth Vera · 3 shared papers, 2017–2022 · strength 0.22
  15. Teresa Mercade Macarulla · 2 shared papers, 2017–2024 · strength 0.21
  16. Carles Pericay · 2 shared papers, 2014–2024 · strength 0.21
  17. Antonio Irigoyen · 3 shared papers, 2016–2018 · strength 0.18
  18. Rocio García‐Carbonero · 1 shared paper, 2024 · strength 0.17
  19. Carolina Torres · 2 shared papers, 2016–2018 · strength 0.13
  20. Jose Carlos Prados · 2 shared papers, 2016–2018 · strength 0.13
  21. Octavio Caba · 2 shared papers, 2016–2018 · strength 0.13
  22. Cristina Jiménez‐Luna · 2 shared papers, 2016–2018 · strength 0.13
  23. Iranzu González‐Borja · 1 shared paper, 2022 · strength 0.13
  24. Joaquín Fernández‐Irigoyen · 1 shared paper, 2022 · strength 0.13
  25. Antonio Viúdez · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.